Trastuzumab
Herceptin (trastuzumab) is an antibody pharmaceutical. Trastuzumab was first approved as Herceptin on 1998-09-25. It is used to treat breast neoplasms and gastrointestinal neoplasms in the USA. It has been approved in Europe to treat breast neoplasms and stomach neoplasms. The pharmaceutical is active against receptor tyrosine-protein kinase erbB-2.
| Trade Name | Herceptin |
|---|---|
| Common Name | Trastuzumab |
| ChEMBL ID | CHEMBL1201585 |
| Indication | breast neoplasms, gastrointestinal neoplasms, stomach neoplasms |
| Drug Class | Monoclonal antibodies: humanized, tumors as target |
